Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
journal contributionposted on 16.11.2018, 00:00 by Philipp M. Cromm, Kusal T. G. Samarasinghe, John Hines, Craig M. Crews
Enzymatic inhibition has proven to be a successful modality for the development of many small-molecule drugs. In recent years, small-molecule-induced protein degradation has emerged as an orthogonal therapeutic strategy that has the potential to expand the druggable target space. Focal adhesion kinase (Fak) is a key player in tumor invasion and metastasis, acting simultaneously as a kinase and a scaffold for several signaling proteins. While previous efforts to modulate Fak activity were limited to kinase inhibitors with low success in clinical studies, protein degradation offers a possibility to simultaneously block Fak’s kinase signaling and scaffolding capabilities. Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. These results underline the potential that PROTACs offer in expanding the druggable space and controlling protein functions that are not easily addressed by traditional small-molecule therapeutics.
Read the peer-reviewed publication
small-molecule drugsFak activitysmall-molecule-induced protein degradationtumor invasionPROTACs offerprotein degradationprotein functionsdruggable spacedruggable target spacePROTAC-Mediated DegradationFak-mediated cell migrationsmall-molecule therapeuticsFak activationPROTAC -3Focal adhesion kinasekinase inhibitorsscaffolding capabilitiesKinase-Independent FunctionsFak degrader